Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 10/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.84 |
| ▸ | AR | P10275 | 9/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clocortolone Pivalate SCHEMBL5120 | 0.91 | PGR (1.00) | PGRHIF1AARCYP3A4ADORA3 | |
| Clocortolone Pivalate SCHEMBL32668843 | 0.91 | PGR (1.00) | PGRHIF1AARCYP3A4ADORA3 | |
| Clocortolone Pivalate SCHEMBL6834795 | 0.91 | PGR (1.00) | PGRHIF1AARCYP3A4ADORA3 | |
| Clocortolone Pivalate SCHEMBL10052573 | 0.91 | PGR (1.00) | PGRHIF1AARCYP3A4ADORA3 | |
| Clocortolone Pivalate SCHEMBL13423591 | 0.91 | PGR (1.00) | PGRHIF1AARCYP3A4ADORA3 | |
| SCHEMBL11119948 | 0.90 | HIF1A (0.69) | PGRHIF1AARCYP3A4ADORA3 | |
| SCHEMBL11327078 | 0.90 | HIF1A (0.69) | PGRHIF1AARCYP3A4ADORA3 | |
| SCHEMBL11119952 | 0.90 | HIF1A (0.69) | PGRHIF1AARCYP3A4ADORA3 | |
| SCHEMBL6650283 | 0.90 | PGR (0.80) | PGRHIF1AARCYP3A4ADORA3 | |
| SCHEMBL10052572 | 0.89 | PGR (0.80) | PGRHIF1AARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152705-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-05-15 | — | — | US | claimed |
| EP-3943073-B1 | BIODEGRADABLE POLYMER MICROPARTICLE CONTAINING STEROID-BASED DRUG AND PREPARATION METHOD THEREFOR | REGENBIOTECH INC (KR) | 2025-03-26 | — | — | EP | claimed |
| CN-119095616-A | Combination therapy comprising anti-IL-23 antibodies and corticosteroids for the treatment of psoriasis | 太阳医药工业有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4463228-A1 | COMBINATION THERAPY COMPRISING AN ANTI-IL-23 ANTIBODY AND A CORTICOSTEROID FOR TREATING PSORIASIS | Sun Pharmaceutical Industries Limited (IN) | 2024-11-20 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-12005051-B2 | Topical roflumilast formulation having improved delivery and plasma half life | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4329849-A1 | INHALER | 3D Engineering Design Limited (GB) | 2024-03-06 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| CN-117222430-A | Treatment of cutaneous lupus erythematosus | 阿斯利康(瑞典)有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-117157326-A | anti-I INF receptor antibody anilurumab for treating lupus nephritis | 阿斯利康(瑞典)有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12005051-B2 | Topical roflumilast formulation having improved delivery and plasma half life | CETP, PDE12, LIPA | PGR 1414/4885HIF1A 3741/4885AR 2522/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | PGR 796/4885HIF1A 50/4885AR 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.